The University of Chicago Header Logo

Connection

Ezra Cohen to Neoplasms

This is a "connection" page, showing publications Ezra Cohen has written about Neoplasms.
Connection Strength

1.871
  1. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. Clin Cancer Res. 2021 02 01; 27(3):689-703.
    View in: PubMed
    Score: 0.253
  2. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019 12 04; 7(1):342.
    View in: PubMed
    Score: 0.238
  3. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.150
  4. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
    View in: PubMed
    Score: 0.143
  5. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.130
  6. mTOR: the mammalian target of replication. J Clin Oncol. 2008 Jan 20; 26(3):348-9.
    View in: PubMed
    Score: 0.105
  7. Forthcoming receptor tyrosine kinase inhibitors. Expert Opin Ther Targets. 2006 Dec; 10(6):793-7.
    View in: PubMed
    Score: 0.097
  8. Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 06 13; 29(12):2210-2219.
    View in: PubMed
    Score: 0.076
  9. ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs. 2001 Dec; 2(12):1770-5.
    View in: PubMed
    Score: 0.068
  10. Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082.
    View in: PubMed
    Score: 0.066
  11. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.054
  12. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2018 06; 33(3):622-626.
    View in: PubMed
    Score: 0.054
  13. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011.
    View in: PubMed
    Score: 0.046
  14. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
    View in: PubMed
    Score: 0.044
  15. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89.
    View in: PubMed
    Score: 0.042
  16. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.040
  17. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84.
    View in: PubMed
    Score: 0.040
  18. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.038
  19. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
    View in: PubMed
    Score: 0.034
  20. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 01; 17(11):3841-9.
    View in: PubMed
    Score: 0.033
  21. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
    View in: PubMed
    Score: 0.033
  22. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
    View in: PubMed
    Score: 0.032
  23. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.
    View in: PubMed
    Score: 0.030
  24. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491.
    View in: PubMed
    Score: 0.014
  25. PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.